RxDoctor Payments Data

Larry Brown, MD

Family Medicine · Jasper, TXNPI 1942276605

Payments from drug & device makers

$1,301in general payments, 2019–2025

Across 75 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$188
  • AbbVie$170
  • Novo Nordisk$156
  • Mylan Specialty L.p.$118
  • Dexcom, Inc.$110
  • AstraZeneca$109
  • plus $450 from 17 others

What the payments were for

  • Food & beverage$1,301100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,301 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$276,748
Medicare patients
468
Services billed
6,619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide164$159,403
EliquisApixaban142$108,859
FarxigaDapagliflozin Propanediol108$81,056
TrulicityDulaglutide55$80,467
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$68,669
JanuviaSitagliptin Phosphate87$54,829
JardianceEmpagliflozin63$52,963
LinzessLinaclotide70$52,492
XareltoRivaroxaban59$49,459
MounjaroTirzepatide30$45,640
MyrbetriqMirabegron66$38,577
EntrestoSacubitril/Valsartan26$29,063
Tresiba Flextouch U-100Insulin Degludec36$27,442
RybelsusSemaglutide20$27,265
RexultiBrexpiprazole30$22,956

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$156$186,669184 claims
Lilly USA, LLCTrulicity, Mounjaro$30$126,10785 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$109$113,915162 claims
GSKTrelegy Ellipta, Breo Ellipta$54$74,98581 claims
MerckJanuvia, Janumet Xr$188$64,656107 claims
Johnson & JohnsonXarelto, Invokamet$22$60,36674 claims
AbbVieLinzess, Lumigan$170$58,73981 claims
NovartisEntresto$19$29,06326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Jasper

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →